Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456951 | 0.89 | ACHE (0.65) | ACHEBCHELPAR1KMT2AL3MBTL1 | |
| SCHEMBL307148 | 0.86 | HTT (0.58) | ACHEBCHEKMT2ARAB9AMAPT | |
| SCHEMBL7413611 | 0.79 | TAS2R14 (0.68) | MAPT | |
| SCHEMBL16706893 | 0.78 | LOXL2 (0.62) | RAB9ATSHRMAPT | |
| SCHEMBL307913 | 0.77 | HTT (0.62) | ACHEBCHEKMT2ATSHRHTT | |
| SCHEMBL305141 | 0.76 | ROCK2 (0.78) | L3MBTL1NPC1RAB9A | |
| SCHEMBL3124357 | 0.75 | LOXL2 (0.55) | RAB9ATSHRMAPTPPARG | |
| SCHEMBL10724882 | 0.75 | KMT2A (0.73) | KMT2AL3MBTL1TSHRMAPTPPARG | |
| SCHEMBL2188210 | 0.75 | SMPD1 (0.76) | KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2063068 | 0.75 | SMN1; SMN2 (0.73) | KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-2114869-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ACHE 357/4885BCHE 416/4885LPAR1 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.